Alprostadil (Caverject/MUSE) Cost in Utah 2026

What Is Alprostadil and How Does It Treat Erectile Dysfunction?

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle in penile arteries, increasing blood flow and producing an erection within 5 to 20 minutes. The FDA approved the intracavernosal form (Caverject) in 1995 and the intraurethral suppository (MUSE) in 1996. Both forms are prescription-only and require a licensed clinician to initiate and supervise treatment. [1]

The drug works by binding to prostaglandin EP receptors on cavernosal smooth muscle, activating adenylyl cyclase, raising intracellular cyclic AMP, and triggering muscle relaxation and arterial dilation. This mechanism operates independently of nitric oxide, making alprostadil effective in men who do not respond to phosphodiesterase-5 (PDE-5) inhibitors such as sildenafil or tadalafil. [2]

Caverject is injected directly into the corpus cavernosum with a fine-gauge needle at doses ranging from 1.25 mcg to 40 mcg per injection. MUSE is a 1.4 mm by 3 mm suppository inserted into the urethra in doses of 125 mcg, 250 mcg, 500 mcg, or 1000 mcg. Response rates differ between the two forms: intracavernosal injection produces erections in 70 to 90% of men, while intraurethral MUSE produces erections sufficient for intercourse in roughly 30 to 65% of men depending on the trial and population studied. [3]

A 2001 Cochrane review of alprostadil for erectile dysfunction confirmed consistent efficacy across organic, psychogenic, and mixed etiologies, with intracavernosal injection outperforming the intraurethral route. [4] The most common adverse event with intracavernosal injection is penile pain, reported in approximately 30 to 37% of users in controlled trials. Priapism (erection lasting more than four hours) occurs in fewer than 1% of cases when doses are properly titrated. [5]

Key Trial Data: What the Evidence Shows

The most frequently cited efficacy study for alprostadil is the Linet and Ogrinc randomized controlled trial published in the New England Journal of Medicine in 1996. [6] In that trial, 296 men with chronic erectile dysfunction of organic origin received intracavernosal alprostadil at doses titrated between 2.5 mcg and 20 mcg. At 12 weeks, 87% of men in the alprostadil group achieved erections sufficient for sexual intercourse, compared with 24% in the placebo group (P<0.001). Patient satisfaction scores on a seven-point scale averaged 4.9 for alprostadil versus 1.9 for placebo.

A separate parallel study published in the same NEJM issue evaluated 1,511 men with erectile dysfunction across a broad spectrum of underlying causes. Alprostadil produced a clinically successful erection in 94% of in-office test injections. [7] Mean duration of erection was 30 minutes at therapeutic doses. These numbers represent the benchmark for what Utah clinicians should expect when selecting alprostadil for appropriate patients.

For MUSE specifically, the FDA-reviewed key trial enrolled 1,511 men across 27 outpatient sites. In-office testing showed 65.9% of men achieved an erection sufficient for intercourse; at-home success rates across three months of use were 48.6%. [8] The FDA label for MUSE documents these figures and instructs clinicians to perform the first administration in a supervised clinical setting to detect hypotension or syncope. [9]

The HealthRX clinical team uses a structured decision pathway when evaluating Utah patients for alprostadil: confirm PDE-5 inhibitor failure or contraindication, review cardiovascular history before initiating any vasoactive agent, perform an in-office dose-titration visit (required for both Caverject and MUSE per FDA labeling), and then determine whether brand or compounded formulation is cost-appropriate given the patient's insurance status and income. This four-step sequence reduces time to first successful home use and helps avoid the most common barriers to adherence, which are cost and inadequate instruction on injection technique.

Alprostadil Pricing in Utah in 2026

Brand alprostadil costs approximately $600 per month at Utah retail pharmacies in 2026, though the exact figure depends on dose, quantity dispensed, and which pharmacy chain fills the prescription. This $600 figure reflects the manufacturer list price for Caverject Impulse (Pfizer) as well as the leading generics.

GoodRx data as of early 2026 show cash prices for Caverject 10 mcg (one kit) ranging from $83 to $110 per single-dose vial across Salt Lake City, Provo, and St. George pharmacies. A typical 30-day supply of four to eight doses reaches $330 to $660 depending on the dose strength. MUSE 500 mcg (six suppositories) lists near $320 to $370 at major Utah chains. [10] Patients should compare prices across Walgreens, Smith's, Harmons, and independent compounding pharmacies before filling.

Generic alprostadil powder for injection became more widely available after Pfizer's Caverject patents matured, and generic manufacturers have applied to list products under ANDA filings with the FDA. [11] Even with a generic, cash prices remain high because alprostadil is a specialty compound requiring cold-chain storage and precise reconstitution. This is one reason compounded alprostadil from 503A pharmacies draws consistent interest from Utah patients.

Utah Medicaid and Alprostadil: Coverage Status

Utah Medicaid does not cover alprostadil for erectile dysfunction. The Utah Division of Medicaid and Health Financing excludes erectile dysfunction medications from its covered drug list, consistent with policies in most state Medicaid programs that follow CMS guidance excluding drugs "used for cosmetic purposes or hair growth" and, by extension, sexual dysfunction treatments. [12]

The CMS Medicaid Drug Policy guidance at 42 CFR 440.120 allows states to exclude drugs used for erectile dysfunction, and Utah exercises that exclusion. [13] Patients covered by Utah Medicaid should therefore expect to pay out-of-pocket or seek copay assistance programs.

Veterans enrolled in VA healthcare in Utah may receive alprostadil through VA formulary if it meets clinical criteria. The VA national formulary lists alprostadil as a non-formulary agent requiring a non-formulary drug request, meaning the prescribing provider must document failure of PDE-5 inhibitors. [14] Patients at the Salt Lake City VA Medical Center or the George E. Wahlen VA should speak with their urologist directly about the non-formulary approval process.

Commercial Insurance Coverage in Utah

Most Utah commercial insurers classify alprostadil as a specialty erectile dysfunction drug requiring prior authorization. Plans on the Utah health exchange (healthcare.gov) vary considerably. SelectHealth, DMBA, and Regence BlueCross BlueShield of Utah each require prior authorization and typically demand documentation that at least two PDE-5 inhibitors were tried at maximum tolerated doses and failed before approving alprostadil. [15]

The American Urological Association 2018 guideline on erectile dysfunction, which remains the active reference standard, states that "second-line therapies, including vacuum erection devices, intraurethral and intracavernosal vasoactive agents, should be offered to patients who fail or cannot tolerate first-line oral therapy." [16] Including this guideline citation in a prior authorization letter from a Utah clinician substantially increases approval rates.

Even when approved, commercial plans frequently impose high specialty drug copays of $80 to $200 per fill. Patients should verify their specific plan's formulary tier for alprostadil by calling the number on the back of their insurance card or using their plan's online formulary tool. Step-therapy requirements may delay access by four to eight weeks while PDE-5 inhibitor trials are documented.

Compounded Alprostadil in Utah: Legal Status and 503A Rules

Compounded alprostadil is legal in Utah when prepared by a state-licensed 503A compounding pharmacy operating under a valid prescription for an individual patient. Utah follows federal 503A regulations under the Drug Quality and Security Act of 2013 (DQSA), which allow compounding pharmacies to prepare alprostadil formulations not commercially available or not commercially practical for a specific patient. [17]

Section 503A of the Federal Food, Drug, and Cosmetic Act requires that compounded preparations: (1) be made from bulk drug substances that appear on the FDA's approved bulk drug list or have been nominated for consideration, (2) be prepared for an identified individual patient based on a valid prescription, and (3) not be essentially a copy of a commercially available product unless a specific clinical reason justifies the deviation. [18]

Alprostadil bulk powder appears on FDA's list of bulk drug substances under consideration for 503A compounding, and multiple Utah 503A pharmacies currently compound alprostadil injection solutions and topical creams under individual patient prescriptions. Topical alprostadil cream (often combined with aminophylline and isosorbide dinitrate in a tri-mix cream) is not FDA-approved but may be compounded under 503A rules when a practitioner documents a specific patient need. [19]

The Utah Division of Occupational and Professional Licensing (DOPL) regulates in-state compounding pharmacies. Out-of-state 503A pharmacies shipping compounded alprostadil into Utah must comply with Utah's pharmacy reciprocity rules and may require registration with Utah DOPL. Patients ordering from an out-of-state 503A pharmacy should verify that pharmacy holds a non-resident pharmacy license from Utah. [20]

Cost for compounded alprostadil from a 503A pharmacy varies widely. Some telehealth platforms that include in-house or affiliated compounding pharmacies offer pricing between $30 and $120 per month for intracavernosal formulations, a fraction of the $600 brand price. However, compounded products are not FDA-approved, do not carry the same sterility guarantees as manufactured drugs, and are not interchangeable with brand Caverject or MUSE. Patients should use compounded alprostadil only from pharmacies that provide Certificates of Analysis (COAs) confirming potency and sterility testing.

Alprostadil via Telehealth in Utah

Utah law permits telehealth prescribing of alprostadil. The Utah Telehealth Act (Utah Code 26-60-101 et seq.) allows licensed Utah clinicians to prescribe schedule and non-schedule prescription drugs via synchronous audio-video visits without requiring an in-person physical examination, provided the clinician can adequately evaluate the patient. [21]

One critical caveat applies: the FDA label for both Caverject and MUSE requires that the first dose be administered in the clinician's office to establish an appropriate dose and monitor for adverse events such as hypotension, priapism, or urethral burning. [22] Telehealth platforms operating in Utah should instruct patients to attend at least one in-person dose-titration visit at a urology clinic or affiliated clinic before self-administering at home.

The Ryan Haight Online Pharmacy Consumer Protection Act does not restrict non-controlled substances, and alprostadil is not a controlled substance, so federal telemedicine prescribing restrictions do not apply. [23] Utah clinicians on platforms such as HealthRX can evaluate erectile dysfunction via telehealth and issue alprostadil prescriptions after reviewing a patient's medical history, current medications, and cardiovascular risk profile.

A 2021 analysis in the Journal of Sexual Medicine found that telehealth-initiated erectile dysfunction treatment showed comparable adherence and patient satisfaction to in-person initiation at 90-day follow-up, with 72% of telehealth patients reporting continued use versus 68% of in-person patients. [24] This supports the clinical appropriateness of telehealth pathways for alprostadil, provided the FDA-mandated first-dose titration is completed.

Manufacturer Savings Cards and Discount Programs in Utah

Pfizer offers a Caverject savings card for commercially insured patients that may reduce out-of-pocket costs to as low as $0 per fill for eligible patients, subject to a maximum annual savings cap. Utah residents with commercial insurance (not Medicaid, Medicare, or any government-funded plan) may be eligible. The savings card is available through Pfizer's patient assistance portal and must be activated before use at the pharmacy. [25]

Patients without insurance may apply for Pfizer's patient assistance program (RxPathways), which provides free medication to qualifying low-income patients. Income thresholds and eligibility criteria change annually; patients should check directly at Pfizer's RxPathways website or call 1-888-4RxPATH. [26]

GoodRx coupons apply to alprostadil at many Utah pharmacies and can reduce cash prices by 20 to 40% at Walgreens, CVS, and Smith's. These coupons are not insurance and cannot be combined with insurance benefits. RxSaver, Blink Health, and NeedyMeds also list alprostadil discount options that Utah residents may redeem at participating pharmacies. [27]

NeedyMeds maintains a database of pharmaceutical manufacturer patient assistance programs. For alprostadil, NeedyMeds lists two active programs as of 2026: the Pfizer RxPathways program for Caverject and a legacy program for MUSE administered through Meda Pharmaceuticals. Eligibility for both programs generally requires income at or below 300% of the federal poverty level and no active prescription drug insurance coverage. [28]

Caverject vs. MUSE: Which Makes More Sense Financially in Utah?

Both Caverject and MUSE carry similar list prices in Utah, but their cost-effectiveness differs based on efficacy, frequency of successful use, and how insurance treats each. Caverject is more likely to produce a reliable erection per use, meaning fewer "wasted" doses per month. MUSE has a lower per-dose success rate (approximately 30 to 65% per use versus 70 to 90% for Caverject), which means patients may use more doses per month to achieve the same number of satisfactory sexual encounters.

A pharmacoeconomic analysis published in 2000 in Pharmacoeconomics calculated the cost per successful intercourse episode for alprostadil ICI at $42 to $68 versus $90 to $140 for MUSE, at then-current prices. [29] Adjusting for 2026 pricing in Utah, the differential likely favors Caverject further given similar list prices but higher MUSE per-episode dose usage.

Patients who have penile injection anxiety or a coagulation disorder may accept MUSE's lower per-episode success rate in exchange for avoiding needles. That clinical preference is valid and should be weighed alongside cost. The AUA guideline notes both forms are reasonable second-line options, and clinician judgment should incorporate patient preference alongside efficacy data. [30]

How to Get Alprostadil in Utah: Step-by-Step

Obtaining alprostadil in Utah involves five concrete steps. First, schedule a urology or men's health appointment, either in-person or via telehealth, with a Utah-licensed provider. Second, complete a cardiovascular risk assessment; men with unstable angina, recent myocardial infarction within six months, or systolic blood pressure below 90 mmHg are not candidates. [31] Third, attend an in-office dose-titration visit as required by FDA labeling. Fourth, obtain the prescription and compare prices across brand (Caverject/MUSE), generic, and compounded 503A options before filling. Fifth, verify insurance coverage or apply for the applicable savings card or patient assistance program before paying cash price.

HealthRX clinicians licensed in Utah can initiate the evaluation and prescription steps via a synchronous audio-video telehealth visit and then coordinate an in-person titration visit at a partnering Utah clinic. Current Utah clinic partnerships include facilities in Salt Lake City, Ogden, and St. George.

Drug Interactions and Safety Considerations

Alprostadil carries a boxed-adjacent warning (not a full black-box warning) for priapism. Any erection lasting more than four hours requires emergency evaluation. The drug must not be used concurrently with other vasoactive intracavernosal agents such as papaverine or phentolamine unless prescribed as a compounded combination (Trimix or Bimix) under physician supervision. [32]

Men taking alpha-1 adrenergic blockers (tamsulosin, terazosin) for benign prostatic hyperplasia face additive hypotension risk and require lower starting doses. Men taking anticoagulants (warfarin, apixaban) may experience increased bruising or hematoma at the injection site and should be counseled on compression technique. [33]

The FDA label warns against use in men with sickle cell anemia, sickle cell trait, multiple myeloma, or leukemia due to elevated priapism risk. Men with a penile implant or significant Peyronie's disease plaques may not be candidates for ICI therapy at standard doses. [34]

A 2019 review in the International Journal of Impotence Research confirmed that alprostadil's cardiovascular safety profile is acceptable in men with stable coronary artery disease, provided blood pressure is monitored at the first in-office dose. [35] Men on nitrates are not contraindicated from alprostadil (unlike with PDE-5 inhibitors), which is one reason alprostadil is specifically valuable in the cardiac patient population.

Storage and Handling in Utah's Climate

Caverject Impulse dual-chamber cartridges should be stored at room temperature (15 to 30 degrees Celsius) and protected from freezing. The reconstituted solution must be used within 24 hours. MUSE suppositories require refrigeration at 2 to 8 degrees Celsius until dispensed and can be stored at room temperature for up to 14 days after dispensing. [36]

Utah's high-desert climate produces summer temperatures that can exceed 40 degrees Celsius in vehicles and storage areas. Patients in St. George, Moab, or rural southern Utah should not leave alprostadil in a car or uninsulated location during summer months, as heat degrades the active prostaglandin and reduces potency. Compounded alprostadil solutions, which lack the stabilizers in brand formulations, may be even more temperature-sensitive; patients should ask their 503A pharmacy for specific temperature tolerance data. [37]